Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2003 1
2005 2
2006 2
2007 1
2008 1
2009 1
2010 2
2011 5
2012 5
2013 3
2014 2
2015 1
2016 1
2017 1
2018 4
2019 2
2020 4
2021 3
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, Galleron N, Huang X, Gencer S, Coen M, Tranah TH, Wendon JA, Bruce KD, Le Chatelier E, Ehrlich SD, Edwards LA, Shoaie S, Shawcross DL. Patel VC, et al. Among authors: edwards la. J Hepatol. 2022 Feb;76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. Epub 2021 Sep 24. J Hepatol. 2022. PMID: 34571050 Free article. Clinical Trial.
Targeting the gut-liver-immune axis to treat cirrhosis.
Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Tranah TH, et al. Among authors: edwards la. Gut. 2021 May;70(5):982-994. doi: 10.1136/gutjnl-2020-320786. Epub 2020 Oct 15. Gut. 2021. PMID: 33060124 Review.
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.
Torp N, Israelsen M, Coenraad M, Papp M, Shawcross D, Korenjak M, Angeli P, Laleman W, Juanola A, Gines P, Trebicka J, Krag A; MICROB-PREDICT Consortium. Torp N, et al. BMJ Open. 2024 Feb 14;14(2):e079309. doi: 10.1136/bmjopen-2023-079309. BMJ Open. 2024. PMID: 38355195 Free PMC article. Clinical Trial.
Treatment of caffeine toxicity with metoprolol.
Li SF, Edwards L, Nguyen V. Li SF, et al. Among authors: edwards l. Am J Emerg Med. 2019 Mar;37(3):562.e5-562.e10. doi: 10.1016/j.ajem.2018.11.038. Epub 2018 Nov 26. Am J Emerg Med. 2019. PMID: 30514596
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
Liu J, MacNaughtan J, Kerbert AJC, Portlock T, Martínez Gonzalez J, Jin Y, Clasen F, Habtesion A, Ji H, Jin Q, Phillips A, De Chiara F, Ingavle G, Jimenez C, Zaccherini G, Husi K, Rodriguez Gandia MA, Cordero P, Soeda J, McConaghy L, Oben J, Church K, Li JV, Wu H, Jalan A, Gines P, Solà E, Eaton S, Morgan C, Kowalski M, Green D, Gander A, Edwards LA, Cox IJ, Cortez-Pinto H, Avery T, Wiest R, Durand F, Caraceni P, Elosua R, Vila J, Pavesi M, Arroyo V, Davies N, Mookerjee RP, Vargas V, Sandeman S, Mehta G, Shoaie S, Marchesi J, Albillos A, Andreola F, Jalan R. Liu J, et al. Among authors: edwards la. Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699. Online ahead of print. Gut. 2024. PMID: 38621924
Understanding Theory of Mind in Deaf and Hearing College Students.
Marschark M, Edwards L, Peterson C, Crowe K, Walton D. Marschark M, et al. Among authors: edwards l. J Deaf Stud Deaf Educ. 2019 Apr 1;24(2):104-118. doi: 10.1093/deafed/eny039. J Deaf Stud Deaf Educ. 2019. PMID: 30597037 Free PMC article.
Bone matrix quality after sclerostin antibody treatment.
Ross RD, Edwards LH, Acerbo AS, Ominsky MS, Virdi AS, Sena K, Miller LM, Sumner DR. Ross RD, et al. Among authors: edwards lh. J Bone Miner Res. 2014 Jul;29(7):1597-607. doi: 10.1002/jbmr.2188. J Bone Miner Res. 2014. PMID: 24470143 Free article.
38 results